Development of multistage recombinant protein vaccine formulations against toxoplasmosis using a new chitosan and porin based adjuvant system

PARMAKSIZ S., Gul A., Alak S. E., Karakavuk M., Can H., Gul C., ...Daha Fazla

INTERNATIONAL JOURNAL OF PHARMACEUTICS, cilt.626, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 626
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.ijpharm.2022.122199
  • Dergi Adı: INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Anahtar Kelimeler: Chitosan, Porins, rGRA1, rBAG1, Particulate adjuvant, Toxoplasmosis, IMMUNE-RESPONSES, DNA VACCINE, CROSS-PRESENTATION, SALMONELLA-TYPHI, DENDRITIC CELLS, PARTICLE-SIZE, IFN-GAMMA, T-CELLS, PARTICULATE VACCINES, PROTECTIVE IMMUNITY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Toxoplasmosis is a global health problem affecting both human and animal populations. The lack of effective treatment makes the development of a vaccine against toxoplasmosis one of the main goals in the management of this disease. In our study, vaccine formulations containing the multistage recombinant antigens, rBAG1 + rGRA1 were developed with a combined adjuvant system consisting of chitosan and Salmonella Typhi porins in micro (MicroAS) and nanoparticulate (NanoAS) forms. BALB/c mice were immunized intraperitoneally with vaccine formulations two times at three-week intervals. Three weeks after the second vaccination, mice were challenged with 7-8 live tissue cysts of the virulent T. gondii PRU strain by oral gavage. Higher cellular uptake by macro-phages and enhanced cellular (IFN-gamma and I-4 in stimulated spleen cells) and humoral (IgG, IgG1, IgG2a) responses were obtained with the adjuvanted formulation, higher with microsystem when compared to that of nanosystem. Microsystem was found to stimulate Th1-polarized immune responses, whereas non-adjuvanted antigens stim-ulated Th2-polarized immune response. The highest survival rate and reduction in cysts numbers and T. gondii DNA were obtained with the adjuvanted antigens. Our study showed that adjuvanted multistage recombinant vaccine systems increase the immune response with strong protection against T. gondii, more profoundly in microparticulate form.